Relmada Competitors
| RLMD Stock | USD 3.65 0.18 4.70% |
Relmada Therapeutics vs Adicet Bio Correlation
Pay attention - limited upside
The correlation between Relmada Therapeutics and ACET is -0.75 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Relmada Therapeutics and ACET in the same portfolio, assuming nothing else is changed.
Moving against Relmada Stock
| 0.54 | HD | Home Depot | PairCorr |
| 0.44 | PSGTF | PT Semen Indonesia | PairCorr |
| 0.44 | MSFT | Microsoft | PairCorr |
| 0.42 | HPQ | HP Inc Aggressive Push | PairCorr |
| 0.36 | PG | Procter Gamble | PairCorr |
Relmada Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Relmada Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Relmada and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Relmada Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Relmada Stock performing well and Relmada Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Relmada Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ACRV | 4.97 | 0.15 | 0.02 | 0.23 | 7.58 | 8.21 | 66.02 | |||
| PMVP | 2.35 | (0.41) | 0.00 | (0.50) | 0.00 | 5.98 | 17.05 | |||
| IMUX | 3.44 | (0.26) | 0.00 | (0.15) | 0.00 | 9.43 | 21.44 | |||
| TCRX | 4.02 | (0.90) | 0.00 | (0.22) | 0.00 | 9.62 | 40.38 | |||
| VXRT | 4.90 | 1.20 | 0.15 | 1.98 | 6.05 | 15.15 | 75.42 | |||
| LITS | 4.23 | (0.84) | 0.00 | (0.38) | 0.00 | 7.62 | 26.34 | |||
| FBIO | 3.20 | 0.31 | 0.08 | 0.21 | 4.21 | 6.63 | 29.21 | |||
| RPTX | 2.16 | 0.56 | 0.24 | 1.81 | 1.47 | 3.95 | 35.71 | |||
| CBUS | 5.06 | 0.68 | 0.11 | 0.53 | 6.09 | 11.03 | 33.18 | |||
| ACET | 3.22 | (0.64) | 0.00 | (0.66) | 0.00 | 6.18 | 16.66 |
Cross Equities Net Income Analysis
Compare Relmada Therapeutics and related stocks such as Acrivon Therapeutics, Pmv Pharmaceuticals, and Immunic Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (29.7 M) | (60.4 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| PMVP | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (25.4 M) | (34.4 M) | (57.8 M) | (73.3 M) | (69 M) | (58.7 M) | (52.8 M) | (55.5 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| TCRX | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (26.1 M) | (48.6 M) | (66.2 M) | (89.2 M) | (127.5 M) | (114.7 M) | (109 M) |
| VXRT | 1000 K | (4.5 M) | (8.7 M) | (8.9 M) | (11 M) | (19.1 M) | (25.4 M) | (12.5 M) | (18 M) | (18.6 M) | (32.2 M) | (70.5 M) | (107.8 M) | (82.5 M) | (66.9 M) | (60.3 M) | (57.2 M) |
| LITS | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (54.5 M) | (31.8 M) | 17.8 M | (15.9 M) | (18.3 M) | (19.3 M) |
| FBIO | (3.8 M) | (36.4 M) | (27.6 M) | (37.2 M) | (20.4 M) | (48.4 M) | (55.1 M) | (66.9 M) | (84.1 M) | (40 M) | (46.5 M) | (64.7 M) | (86.6 M) | (60.6 M) | (46 M) | (41.4 M) | (43.5 M) |
| RPTX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (14.3 M) | (27.2 M) | (53.4 M) | (106.9 M) | (29 M) | (93.8 M) | (84.7 M) | (76.2 M) | (80 M) |
| CBUS | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (12.1 M) | (26 M) | (27.9 M) | (39.6 M) | (44.8 M) | (29.2 M) | (16.9 M) | (267.6 M) | (251.4 M) | (226.2 M) | (214.9 M) |
| ACET | 13.5 M | 9 M | 17 M | 22.3 M | 22.3 M | 29 M | (1000) | (33.8 M) | (9.3 M) | (28.1 M) | (36.7 M) | (62 M) | (69.8 M) | (142.7 M) | (117.1 M) | (105.4 M) | (100.1 M) |
Relmada Therapeutics and related stocks such as Acrivon Therapeutics, Pmv Pharmaceuticals, and Immunic Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Relmada Therapeutics financial statement analysis. It represents the amount of money remaining after all of Relmada Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Relmada Therapeutics Competitive Analysis
The better you understand Relmada Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Relmada Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Relmada Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Relmada Therapeutics Competition Performance Charts
Five steps to successful analysis of Relmada Therapeutics Competition
Relmada Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Relmada Therapeutics in relation to its competition. Relmada Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Relmada Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Relmada Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Relmada Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Relmada Therapeutics position
In addition to having Relmada Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marijuana Thematic Idea Now
Marijuana
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Relmada Therapeutics Correlation with its peers. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Will Pharmaceuticals sector continue expanding? Could Relmada diversify its offerings? Factors like these will boost the valuation of Relmada Therapeutics. Anticipated expansion of Relmada directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Relmada Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Relmada Therapeutics's market price often diverges from its book value, the accounting figure shown on Relmada's balance sheet. Smart investors calculate Relmada Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Relmada Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Relmada Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Relmada Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.